| scholarly article | Q13442814 |
| P50 | author | Robert Z Orlowski | Q91428664 |
| P2093 | author name string | H Wang | |
| J Yang | |||
| M Wang | |||
| H Y Lin | |||
| V Baladandayuthapani | |||
| S K Thomas | |||
| R J Jones | |||
| J J Shah | |||
| D M Weber | |||
| C C Bjorklund | |||
| I Kuiatse | |||
| P2860 | cites work | Identification of a primary target of thalidomide teratogenicity | Q24302178 |
| Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Q24614147 | ||
| Wnt/beta-catenin signaling: components, mechanisms, and diseases | Q24630938 | ||
| A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide | Q26865089 | ||
| CD44: from adhesion molecules to signalling regulators | Q28201701 | ||
| Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway | Q28505373 | ||
| Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Q30433139 | ||
| Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides | Q30454570 | ||
| A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities | Q33324196 | ||
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
| Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma | Q33386405 | ||
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma | Q33389111 | ||
| Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients | Q33680252 | ||
| Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. | Q33922745 | ||
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. | Q34210005 | ||
| Lenalidomide after stem-cell transplantation for multiple myeloma | Q34273726 | ||
| Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death | Q34480149 | ||
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
| Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide | Q34719436 | ||
| Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells | Q35128711 | ||
| Hyaluronan-CD44 interactions as potential targets for cancer therapy. | Q35194441 | ||
| Second malignancies after multiple myeloma: from 1960s to 2010s | Q35891594 | ||
| Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma | Q36110746 | ||
| Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides | Q36141838 | ||
| Clonal competition with alternating dominance in multiple myeloma. | Q36141846 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer | Q36620617 | ||
| Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance | Q36976346 | ||
| CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer | Q37725026 | ||
| Targeting Wnt signaling: can we safely eradicate cancer stem cells? | Q37763415 | ||
| CD44 in hematological neoplasias | Q37831812 | ||
| Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance | Q37847694 | ||
| Lenalidomide in multiple myeloma: Current status and future potential | Q38013995 | ||
| Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities | Q39919533 | ||
| Retinol Increases beta-catenin-RXRalpha binding leading to the increased proteasomal degradation of beta-catenin and RXRalpha | Q39987285 | ||
| CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. | Q40035276 | ||
| Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. | Q40161286 | ||
| Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell | Q40174918 | ||
| IL-6 regulates CD44 cell surface expression on human myeloma cells | Q40579834 | ||
| Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma | Q42280442 | ||
| All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma. | Q42548500 | ||
| Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma | Q43726973 | ||
| Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial | Q44908715 | ||
| Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). | Q46118120 | ||
| ATRA-inhibited proliferation in glioma cells is associated with subcellular redistribution of beta-catenin via up-regulation of Axin | Q46793459 | ||
| Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma | Q46920675 | ||
| Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma | Q57903998 | ||
| Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 | ||
| Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration | Q77850389 | ||
| Multiple myeloma | Q82521422 | ||
| All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway | Q84234192 | ||
| The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma | Q84497856 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 2 | |
| P921 | main subject | cell adhesion | Q187640 |
| multiple myeloma | Q467635 | ||
| P304 | page(s) | 373-383 | |
| P577 | publication date | 2013-06-13 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications | |
| P478 | volume | 28 |
| Q47584543 | A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas |
| Q33436890 | A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens |
| Q38714809 | ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR). |
| Q92099049 | BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment |
| Q57191729 | CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance |
| Q93189835 | CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1 |
| Q34251497 | CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells |
| Q24305602 | Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors |
| Q38895636 | Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells |
| Q47144929 | Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes |
| Q50100772 | Comparative Analysis of Quantitative Parameters of Expression of the Retinoic Acid Nuclear Receptor RARα Gene and APE1/YB-1/MDR1 Pattern Genes in Patients with Newly Detected Multiple Myeloma |
| Q27692033 | Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms |
| Q38932298 | Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche |
| Q33715651 | FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through Tankyrases |
| Q96576366 | Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns |
| Q98224778 | Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma |
| Q36544516 | HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide |
| Q92027921 | High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment |
| Q41072852 | Identification of subtype specific miRNA-mRNA functional regulatory modules in matched miRNA-mRNA expression data: multiple myeloma as a case. |
| Q37458756 | Induction of chemoresistance by all-trans retinoic acid via a noncanonical signaling in multiple myeloma cells |
| Q28542684 | Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 |
| Q27025213 | Killing me softly--future challenges in apoptosis research |
| Q39038744 | Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C. |
| Q46345708 | MUC1-C is a target in lenalidomide resistant multiple myeloma |
| Q35171777 | Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma |
| Q39185604 | Mechanisms of Resistance in Multiple Myeloma |
| Q58595932 | NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q89040090 | Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells |
| Q36665156 | Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers |
| Q35796527 | Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. |
| Q48015915 | Retinoic acid, CYP26, and drug resistance in the stem cell niche |
| Q64232853 | Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma |
| Q38853857 | Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma |
| Q40643079 | Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells |
| Q35214544 | Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells |
| Q36444233 | The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma |
| Q39297348 | The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia |
| Q38237446 | The potential of miRNAs as biomarkers for multiple myeloma |
| Q49114034 | The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma |
| Q38734491 | The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells |
| Q37171812 | Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling |
| Q90598650 | Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination |
| Q92538517 | WNT Signaling in Tumors: The Way to Evade Drugs and Immunity |
| Q54956715 | Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. |
Search more.